CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 201 enrolled
Drug / intervention
Omadacycline +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03757234
NCT03757234Phase 2Completed

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of iv or iv/po Omadacycline and iv/po Levofloxacin in the Treatment of Adults With Acute Pyelonephritis.

Paratek Pharmaceuticals Inc·interventional·Posted Nov 28, 2018·Updated Jul 7, 2020

In Brief

A Phase 2 clinical trial evaluating Omadacycline and Levofloxacin for Acute Pyelonephritis. Completed, enrolled 201 participants across 31 sites in 4 countries.

Detailed Summary

The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGeorgia, Latvia, Russia, Ukraine
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 28, 2018
Enrollment StartNov 19, 2018
Primary CompletionJun 26, 2019
Study CompletionJul 24, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.6 years ago

Interventions

Omadacyclinedrug

po tablets

Levofloxacindrug

iv solution/po tablets

Omadacyclinedrug

iv solution